Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients
Open Access
- 22 May 2013
- journal article
- viral hepatitis
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hepatology
- Vol. 58 (4), 1270-1276
- https://doi.org/10.1002/hep.26488
Abstract
Vitamin D is an important immune modulator that plays an emerging role in inflammatory and metabolic liver diseases, including infection with hepatitis C virus (HCV). In contrast, the relationship between vitamin D metabolism and chronic hepatitis B (CHB) is less well characterized. Therefore, we quantified 25(OH)D3 serum levels in a cohort of 203 treatment‐naïve patients with chronic hepatitis B virus (HBV) infection and tested for their association with clinical parameters of CHB. Of 203 patients, 69 (34%), 95 (47%), and 39 (19%) had severe vitamin D deficiency (25(OH)D3 3 ≥10 and 3 ≥20 ng/mL), respectively. In both uni‐ and multivariate analyses, HBV DNA viral load (log10 IU/mL) was a strong predictor of low 25(OH)D3 serum levels (P = 0.0007 and P = 0.000048, respectively) and vice versa. Mean 25(OH)D3 serum concentrations in patients with HBV DNA P < 0.00001). In addition, hepatitis B early antigen (HBeAg)‐positive patients had lower 25(OH)D3 serum levels than HBeAg‐negative patients (P = 0.0013). Finally, 25(OH)D3 and HBV DNA serum levels showed inverse seasonal fluctuations. Conclusion: Low 25(OH)D3 serum levels are associated with high levels of HBV replication in patients with CHB. This represents a major difference from chronic hepatitis C, where numerous previous studies have shown a lack of correlation between HCV viral load and vitamin D serum levels. Inverse seasonal fluctuations of 25(OH)D3 and HBV DNA serum levels are suggestive of a functional relationship between both variables. (Hepatology 2013;58:1270–1276)This publication has 30 references indexed in Scilit:
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistanceLiver International, 2013
- Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis BGut, 2012
- EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infectionJournal of Hepatology, 2012
- Vitamin D InsufficiencyThe New England Journal of Medicine, 2011
- Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?Liver International, 2011
- A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolutionGenome Research, 2010
- The Yin and Yang of vitamin D receptor (VDR) signaling in neoplastic progression: Operational networks and tissue-specific growth controlBiochemical Pharmacology, 2010
- Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analoguesJournal of Hepatology, 2009
- Hepatitis B Virus InfectionThe New England Journal of Medicine, 2008